186 assets in Her2-Receptor Negative Breast Cancer

Therapeutic assets addressing Her2-Receptor Negative Breast Cancer, rated under Floatz methodology v0.2 and sorted by current rating.

Asset	Sponsor	Phase	Rating
Copanlisib Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Coriolus Versicolor Extract Her2-Receptor Negative Breast Cancer	Mayo Clinic	P2	CCC (53)
Decitabine Her2-Receptor Negative Breast Cancer	Virginia Commonwealth University	P2	CCC (53)
Fes F-18 Her2-Receptor Negative Breast Cancer	University of Washington	P2	CCC (53)
FFNP Her2-Receptor Negative Breast Cancer	University of Washington	P2	CCC (53)
Fluorouracilum Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Imlunestrant Her2-Receptor Negative Breast Cancer	Jonsson Comprehensive Cancer Center	P2	CCC (53)
Imp-321 Her2-Receptor Negative Breast Cancer	George Washington University	P2	CCC (53)
Ipatasertib Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Neratinib Maleate Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Nilotinib Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Panitumumab Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Retinoic Acid Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (53)
Selumetinib Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Sotorasib Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (53)
Utidelone Her2-Receptor Negative Breast Cancer	Biostar Pharma, Inc.	P2	CCC (53)
Catequentinib Her2-Receptor Negative Breast Cancer	Sun Yat-sen University	P2	CCC (52)
Dan-222 Her2-Receptor Negative Breast Cancer	Dantari, Inc.	P2	CCC (52)
Dapagliflozin Her2-Receptor Negative Breast Cancer	Yale University	P2	CCC (52)
Dexasone Her2-Receptor Negative Breast Cancer	MedSIR	P3	CCC (52)
Duloxetine Her2-Receptor Negative Breast Cancer	European Organisation for Research and Treatment of Cancer - EORTC	P3	CCC (52)
Entinostat Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P3	CCC (52)
Furosemide Her2-Receptor Negative Breast Cancer	European Organisation for Research and Treatment of Cancer - EORTC	P3	CCC (52)
Oxaliplatin Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (52)
Paclitaxel Trevatide Her2-Receptor Negative Breast Cancer	Angiochem Inc	P3	CCC (52)
Pertuzumab Her2-Receptor Negative Breast Cancer	University of Chicago	P2	CCC (52)
Trastuzumab Deruxtecan Her2-Receptor Negative Breast Cancer	Kristina A. Fanucci	P2	CCC (52)
Tucatinib Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (52)
Zanidatamab Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (52)
Metformin Her2-Receptor Negative Breast Cancer	The Methodist Hospital Research Institute	P2	CCC (51)
mk-2206 Her2-Receptor Negative Breast Cancer	National Cancer Institute (NCI)	P2	CCC (51)
Zotatifin Her2-Receptor Negative Breast Cancer	Jennifer Lee Caswell-Jin	P2	CCC (51)
9mw2821 Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Anti-Pd-L1 Monoclonal Antibody Shr-1316 Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
arx788 Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Benmelstobart Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Datopotamab Deruxtecan Her2-Receptor Negative Breast Cancer	Ana C Garrido-Castro, MD	P2	CCC (48)
Dostarlimab Her2-Receptor Negative Breast Cancer	Dana-Farber Cancer Institute	P2	CCC (48)
Encequidar Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Fianlimab Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
gi-102 Her2-Receptor Negative Breast Cancer	GI Innovation, Inc.	P1/2	CCC (48)
Gsk 5733584 Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
hb1801 Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Hrs-1167 Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Hrs-4508 Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Hrs-6209 Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
ibi354 Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Immunoglobulin G1, Anti-(Human Epidermal Growth Factor Receptor Her2) (Human-Mus Musculus Monoclonal Shr-1805 ?1-Chain), Complex With Human-Mus Musculus Monoclonal Shr-1805 ?-Chain, Dimer, Thioether With N-[6-(3-Mercapto-2,5-Dioxo-1-Pyrrolidinyl)-1-Oxohexyl]Glycylglycyl-L-Phenylalanyl-N-[[(1R)-1-Cyclopropyl-2-[[(1S,9S)-9-Ethyl-5-Fluoro-2,3,9,10,13,15-Hexahydro-9-Hydroxy-4-Methyl-10,13-Dioxo-1H,12H-Benzo[De]Pyrano[3?,4?:6,7]Indolizino[1,2-B]Quinolin-1-Yl]Amino]-2-Oxoethoxy]Methyl]Glycinamide Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)
Immunoglobulin G4, Anti-(Human Programmed Cell Death Protein 1) (Human Monoclonal Regn2810 Heavy Chain), Disulfide With Human Monoclonal Regn2810 .Kappa.-Chain, Dimer Her2-Receptor Negative Breast Cancer	QuantumLeap Healthcare Collaborative	P2	CCC (48)
Ivonescimab Her2-Receptor Negative Breast Cancer	Fudan University	P2	CCC (48)

Showing 51 to 100 of 186 assets

PreviousPage 2 of 4Next